REPL - Replimune Group, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Replimune Group, Inc.

18 Commerce Way
Woburn, MA 01801
United States

Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Mr. Philip Astley-SparkeExec. Chairman, Sec. & Treasurer573.59kN/A1971
Dr. Robert CoffinPres, CEO & Director716.99kN/A1965
Dr. Colin LoveChief Operating Officer419.37kN/A1958
Dr. Howard L. Kaufman F.A.C.S., M.D., M.B.A.Chief Medical Officer548.1kN/A1961
Stephen GorgolChief Accounting OfficerN/AN/A1959
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Replimune Group, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.